Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) Gross Margin (2022 - 2025)

Historic Gross Margin for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to 22.87%.

  • 60 Degrees Pharmaceuticals' Gross Margin fell 403200.0% to 22.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.44%, marking a year-over-year increase of 14400.0%. This contributed to the annual value of 36.67% for FY2024, which is 1238200.0% up from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Gross Margin stood at 22.87% for Q3 2025, which was down 403200.0% from 50.41% recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Gross Margin ranged from a high of 538.03% in Q4 2022 and a low of 325.81% during Q1 2023
  • Moreover, its 4-year median value for Gross Margin was 22.89% (2024), whereas its average is 8.41%.
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -5544100bps in 2023, then skyrocketed by 3638900bps in 2024.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Gross Margin stood at 538.03% in 2022, then plummeted by -103bps to 16.37% in 2023, then skyrocketed by 412bps to 51.13% in 2024, then plummeted by -145bps to 22.87% in 2025.
  • Its Gross Margin was 22.87% in Q3 2025, compared to 50.41% in Q2 2025 and 55.2% in Q1 2025.